International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 1 , Pages 24-29 , 1 January 2009

Effect of Family History on Outcomes in Patients Treated With Definitive Brachytherapy for Clinically Localized Prostate Cancer

  • Christopher A. Peters, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY
    • Corresponding Author InformationReprint requests to: Christopher Albert Peters, M.D., Department of Radiation Oncology, Mount Sinai School of Medicine, 1184 5th Avenue, Box 1236, New York, NY 10029. Tel: (212) 241-7501; Fax: (212) 410-7194
    • ,
  • Richard G. Stock, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY
    • ,
  • Seth R. Blacksburg, M.D., M.B.A.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY
    • ,
  • Nelson N. Stone, M.D.

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, NY

Received 25 February 2008 ,Revised 1 April 2008 ,Accepted 7 April 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Ghadirian P, Howe GR, Hislop TG, et al. Family history of prostate cancer: A multi-center case-control study in Canada. Int J Cancer. 1997;70:679–681
  3. Spitz MR, Currier RD, Fueger JJ, et al. Familial patterns of prostate cancer: A case-control analysis. J Urol. 1991;146:1305–1307
  4. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337–347
  5. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol. 1993;150:797–802
  6. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol. 1996;144:1041–1047
  7. Bauer JJ, Srivastava S, Connelly RR, et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology. 1998;51:970–976
  8. Hanus MC, Zagars GK, Pollack A. Familial prostate cancer: Outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys. 1999;43:379–383
  9. Kupelian PA, Kupelian VA, Witte JS, et al. Family history of prostate cancer in patients with localized prostate cancer: An independent predictor of treatment outcome. J Clin Oncol. 1997;15:1478–1480
  10. Kupelian PA, Reddy CA, Reuther AM, et al. Aggressiveness of familial prostate cancer. J Clin Oncol. 2006;24:3445–3450
  11. Ray ME, Dunn RL, Cooney KA, et al. Family history of prostate cancer and relapse after definitive external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2003;57:371–376
  12. Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology. 1998;52:735–738
  13. Roehl KA, Loeb S, Antenor JA, et al. Characteristics of patients with familial vs. sporadic prostate cancer. J Urol. 2006;176:2438–2442discussion 2442
  14. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–2693
  15. Fleming I, Cooper J. AJCC 1992 staging system. Philadelphia: Lippincott-Raven; 1992;
  16. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219–225
  17. Stone NN, Stock RG. Prostate brachytherapy: Treatment strategies. J Urol. 1999;162:421–426
  18. Peters CA, Stock RG, Cesaretti JA, et al. TGFB1 Single Nucleotide Polymorphisms are Associated with Adverse Quality of Life in Prostate Cancer Patients Treated with Radiotherapy. Int J Radiat Oncol Biol Phys. 2007;
  19. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352–1359
  20. Stock RG, Stone NN, Cesaretti JA, et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  21. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  22. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  23. Kupelian PA, Klein EA, Witte JS, et al. Familial prostate cancer: A different disease?. J Urol. 1997;158:2197–2201
  24. Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA. 1997;278:1251–1255

 Presented at the American Society for Therapeutic Radiology and Oncology 49th Annual Meeting, Oct 27–Nov 1, 2007, Los Angeles, CA.

 Conflict of interest: none.

PII: S0360-3016(08)00768-2

doi: 10.1016/j.ijrobp.2008.04.031

International Journal of Radiation Oncology * Biology * Physics
Volume 73, Issue 1 , Pages 24-29 , 1 January 2009

Article Tools

* Image Usage & Resolution